CaM Kinase II (CaMKII, Calcium-dependent Calmodulin Protein Kinase II) Activation
The CaM Kinase II activation study is a cell stimulation assay which measures the ability of the antibodies in serum to stimulate the production of the enzyme CaM Kinase II which, in turn, upregulates the production and release of neurotransmitters such as dopamine, serotonin, epinephrine and norepinephrine. This test measures calcium/calmodulin-dependent protein kinase activity using a neuronal cell line and compares the measured calcium/calmodulin-dependent protein kinase activity to a normal control calcium/calmodulin-dependent protein kinase activity.
The Cunningham Panel™ tests measure human serum Immunoglobulin G (IgG) levels by Enzyme-Linked ImmunoSorbent Assay (ELISA) directed against: Dopamine D1 Receptor (DRD1), Dopamine D2L Receptor (DRD2L), Lysoganglioside GM1 (Lyso-GM1) and Tubulin (TUB). ELISA results are determined by measuring the colorimetric intensity at a specific wavelength which is directly proportional to the amount of antibody in the sample. The fifth assay of this panel measures the specific activity of calcium/calmodulin-dependent protein kinase II (CaM KII) induced by the patient’s serum in cultured human neuronal cell lines compared to controls. This panel measures the level of these antibodies, and the ability of the patient’s sera to stimulate CaM KII at a single point in time. The Cunningham Panel™ of Tests is a proprietary test panel exclusively offered by Moleculera Labs. For more information please see www.moleculeralabs.com.
- As an aid in diagnosis and management of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS)
- As an aid in diagnosis and management of pediatric acute-onset neuropsychiatric syndrome (PANS)
- As an aid in diagnosis and management of Sydenham's chorea (post Rheumatic Fever)
- As an aid in diagnosis and management of Autism spectrum disorder, specifically regressive autism, that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of treatment resistant psychiatric illnesses and symptoms that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of chronic depression that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of anxiety disorders that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of ADHD/ADD that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of OCD that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of Tourette’s Syndrome that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of bipolar depression that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of new onset enuresis/incontinence that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of rage disorder that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of ODD that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of behavioral regression that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of cognitive decline that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of sensory abnormalities that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of dysgraphia that could have an anti-neuronal autoimmune basis
- As an aid in diagnosis and management of anorexia that could have an anti-neuronal autoimmune basis
If any one (1) or more of these five (5) assay values is elevated, it may indicate a clinically significant autoimmune neurological condition.
Note: It is important to note that the degree of elevation in assay values may not necessarily correlate with degree of symptom severity. Any value above normal ranges may correlate with symptomatology. Results may vary depending on the patient’s condition and status, whether they are on immunosuppressive agents, corticosteroids or other immune modulatory therapy, and the length of time post treatment.
Reference ranges based on pediatric control group:
| Anti-Dopamine Receptor D1 (titer) | Anti-Dopamine Receptor D2L (titer) | Anti-Lysoganglioside GM1 (titer) | Anti-Tubulin (titer) | CaM Kinase II (% of baseline) | |
| Normal Ranges | 500 - 2,000 | 2,000 - 8,000 | 80 - 320 | 250 - 1,000 | 53 - 130 |
| Normal Mean | 1,056 | 6,000 | 147 | 609 | 95 |
Radiometrically tagged cells methodology.
Simply, enzymatic activity is measured using the CaMKII assay system (Promega, Madison, WI) according to manufacturer's instructions. Cell lysate is incubated with peptide substrate and ATP32 for 2minutes at 30°C (Kirvan, 2003 #1570). The sample is spotted onto the capture membrane and washed. Radioactivity retained on the membrane is determined by scintillation counting. The specific activity of the enzyme in pmol/min/μg is determined, and the percentage activity above baseline is calculated. Both positive and negative sera and a baseline control to measure constitutive enzyme activity are used in the standardization and calculation of the results of the test. CaMKII assay results are reported as percentages relative to the basal rate (activity determined in the absence of serum), normalized based upon the protein concentration determined for each cellular lysate.
Serum (Red top tube).
4-5 mL serum collected in red-top glass tube with no additives or gel barrier. Ship on two fully frozen 8-ounce ice packs, overnight only Monday-Thursday. Do not ship on Friday or before a US holiday.
Stability
- Frozen: 1 year
- J Child Adolesc Psychopharmacol. 2015;25(1):76-85. [PMID:25658702]
- J Child Adolesc Psychopharmacol. 2015;25(1):3-13. [PMID: 25325534]
- Nature Medicine. 2003;9(7):914-920. [PMID: 12819778]
- PLoS One. 2013;8(9):e73516. [PMID: 24073196]
- Acta Physiol (Oxf). 2016;216(1):90-100. [PMID: 26454143]
- Immunology. 2007;178:7412-7421. [PMID: 17513792]